



RECEIVED  
JAN 03 2003  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH  
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE  
ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS,  
WASHINGTON, D.C. 20231, ON DECEMBER 19, 2002

AGENT/ATTORNEY FOR APPLICANT

DATE

Attorney Docket No. B2368C4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Hindley, et al.

Application No.: 08/458, 033

Filed: June 1, 1995

For: Novel Compounds

Group No.: 1626

Examiner: Robert Gerstl

Commissioner for Patents

Washington, DC 20231

**RESPONSE TO FINAL OFFICE ACTION**  
**SUBMITTED PURSUANT TO 37 CFR 1.129(a)**

This is responsive to the final Office Action mailed on May 3, 2002, setting a three (3) month period for response (hereinafter also referred to as the "Office Action"). A Notice of Appeal and a Petition to extend the time for response for a period of three (3) months was filed on October 29, 2002. Applicants now respectfully request entry and consideration of the following amendment being submitted in accordance with 37 CFR 1.129(a).

**IN THE CLAIMS:**

- Please cancel claims 1-12 without prejudice to or disclaimer of their subject matter.
- Please add the following new claims:

17. (new) A method for the treatment of type II diabetes in a human or non-human mammal which comprises administering an effective, non-toxic amount of a compound which is selected from 5-(4-[2-(N-methyl-N-(2-